Kryptos Biotechnologies develops photothermal heating technology that uses light to generate heat and control temperature for molecular diagnostic devices and life‑science instruments. Its PCR‑based point‑of‑care system delivers a sample‑to‑answer in about 20 minutes while aiming to match lab accuracy. The company intends to use the Series A proceeds to advance clinical studies of respiratory combo tests and pursue FDA approval by 2025. Kryptos has entered a strategic partnership with Osang Healthcare for manufacturing and distribution of its product. The company is led by CEO Jinyong Lee and is based in Hayward, California. It raised $10M in the reported financing to support clinical and regulatory milestones.

Total raised

$10M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2024